Literature DB >> 19433693

Time for the medical profession to act: new policies needed now on interactions between pharmaceutical companies and physicians.

Philip Greenland.   

Abstract

Mesh：

Year:  2009        PMID： 19433693     DOI： 10.1001/archinternmed.2009.72

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN： 0003-9926


× No keyword cloud information.
  4 in total

1.  Physicians-Pharmaceutical Sales Representatives Interactions and Conflict of Interest: Challenges and Solutions.

Authors:  Avinash R Patwardhan
Journal:  Inquiry       Date:  2016-09-16       Impact factor: 1.730

2.  Mandatory disclosure of pharmaceutical industry-funded events for health professionals.

Authors:  Jane Robertson; Ray Moynihan; Emily Walkom; Lisa Bero; David Henry
Journal:  PLoS Med       Date:  2009-11-03       Impact factor: 11.069

3.  Prevention of cardiovascular disease: why do we neglect the most potent intervention?

Authors:  Emmanuel Stamatakis; Richard Weiler
Journal:  Heart       Date:  2009-11-05       Impact factor: 5.994

Review 4.  Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians' attitudes and prescribing habits: a systematic review.

Authors:  Freek Fickweiler; Ward Fickweiler; Ewout Urbach
Journal:  BMJ Open       Date:  2017-09-27       Impact factor: 2.692
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.